(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage
biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary
technological platform DOS47, today announced financial results for the 2022 fiscal year ended July 31, 2022.